The age of aseptic has arrived in earnest, and as evidenced by several data markers, it’s a best practices bell that can never be unrung. 

The first clang – and perhaps the loudest – came with the August 2023 implementation of the European Union’s GMP Annex 1, a set of stringent updates to Good Manufacturing Practices (GMPs) for sterile drug products. The guidelines amount to an all-hands-on-deck call for heightened contamination prevention and comprise aptly named elements like Contamination Control Strategy (CCS) and Quality Risk Management (QRM), as well as the more widespread utilization of modern barrier technologies like Isolators and Restricted Access Barrier Systems (RABS).

Back in the United States, this opening salvo was amplified by bells of another sort: alarm bells. From 2023 to 2024, sterility-related observations from the Food and Drug Administration (FDA) skyrocketed, driven by heightened regulatory scrutiny, new technologies, and poor practices in some compounding facilities. Notices concerning production record reviews jumped an astonishing 171% year over year. Observations involving microbiological contamination climbed more than 80%, while those for design and construction shortcomings spiked 62%.

The takeaway is clear: while the FDA isn’t strictly adhering to EU GMP Annex 1, global harmonization efforts – such as those defined in the Pharmaceutical Inspection Co-operation Scheme (PIC/S) – are prompting a crackdown on mounting sterility concerns. And since FDA played an active role in helping to draft the EU guidelines, it’s no wonder that its inspectors are now examining quality control through an Annex 1 lens.

Regardless of Annex 1, however, FDA’s shorter leash concerning aseptic manufacturing has been a decade-long trend. In fact, insufficient sterility was the leading cause of FDA pharma recalls from 2012 through 2023. It stands to reason that this single-issue dominance will only be exacerbated as FDA zeroes in even more stringently on sterility and aseptic production practices. 

Encouragingly, these alarm bells seem to be serving their intended purpose: waking the industry up to the need for more thorough aseptic manufacturing and product sterility. Numbers don’t lie – and the industry is by no means lying still. In 2025, the worldwide aseptic fill-finish market was just shy of $6.5 billion. By 2026, it is expected to eclipse $7 billion and, by 2034, reach $14 billion. That’s a compound annual growth rate (CAGR) of nearly 9%, strong enough to more than double the segment’s size in a mere decade. 

The FDA is doubling down – and the market is doubling, period. And amid this elevated emphasis on sterility, the FDA is strongly supporting isolator technology and RABS as a comparably clear path to achieving greater sterility. Unlike alternative aseptic manufacturing methods, such as conventional cleanrooms, regulators are increasingly seeing the value of creating physical barriers that isolate critical processing areas from human operators – an approach long recognized as effective in reducing contamination risks.

Economics 101 dictates that all this demand will impact supply – and not necessarily in a favorable way for pharma manufacturers. As more drugs require aseptic production and processing under more closely scrutinized conditions, the prospect of an infrastructure capacity crunch becomes likely. In such a scenario, pharma manufacturers risk finding themselves settling for solutions that, while certainly functional, are a less-than-ideal fit for meeting current or near-future needs. 

Separate from the Rest: The Unique Benefits of Isolators

Over the same decade that will see the aseptic fill-finish market double, the therapies being filled and finished will become ever more sophisticated. Many advanced therapies already require tailored, even customized production approaches, layering additional complexity atop an already constrained, restricted infrastructure market. These factors – some known, some yet to be revealed – will make finding the best-possible sterility solutions even more challenging.

Cell & gene therapies, antibody-drug conjugates, CAR-T therapies, and radiopharmaceuticals comprise the extraordinary breadth and depth of next-generation drugs currently in the pharmaceutical pipeline. They will require an approach to aseptic manufacturing and processing that is versatile, practical and, most of all, safe and sterile. Notably, these requirements all showcase the FDA’s elevation of isolator technology as a preferred method. 

First and foremost, isolators provide exceptional protection for both drugs and production personnel. When compared to its chief competition – cleanrooms – the reason is simple: people enter cleanrooms, but do not enter isolators. “More people, more risk” is becoming a sterility mantra, one chanted increasingly loud. 

In a sector where HPAPI is measured in nanograms, what workers can’t see can indeed hurt them; the same goes for sterility and the microorganisms that adversely affect it. By placing a fixed, rigid barrier between drugs and workers (and through rugged, strictly tested glove systems), isolators can inherently achieve even Grade A/ISO Class 5 containment – a level that conventional cleanrooms require a labor-intensive layered approach to provide. 

This leads directly into the second most pivotal benefit: isolators are versatile. With the number of advanced therapies utilizing HPAPIs set to increase exponentially in the coming years, aseptic manufacturing solutions will need to be nimble both vertically and horizontally. In other words, such solutions must be capable of handling not only a wide range of formats and delivery devices, but also the full scale of containment levels – i.e. Grade A, B, C and D. The ability to shift between various containment levels and production setups also comes into play, given the small batch sizes inherent in pre-clinical and early-phase investigational drugs. 

And of course, it isn’t merely the therapies themselves that require flexibility in production processes: their containers and delivery devices do as well. The more advanced, delicate and high-leverage next-generation treatments become, the further they drift from anything resembling a “one format fits all” approach to their filling and finishing. 

For starters, many new therapies will inevitably evolve from single to multiple formats, exponentially complicating production. Right-sizing also comes into play and, increasingly, means not only fitting a delivery device to the dosage but also to its eventual administrator; this holds especially true with self-administered drugs. Unsurprisingly, the material properties of containers and delivery devices also are becoming more sophisticated, with the goal of elevating both product protection and sustainability metrics.  

In meeting these broadening requirements, isolators are not only more expediently flexible than cleanrooms, but also significantly more compact. If time equals money, so does floorspace: with aseptic manufacturing poised to grow precipitously, pharma companies will seek sterility solutions that optimize production space and, by extension, maximize output and profit – all without sacrificing mission-critical safety for both personnel and drug products. 

Another thing that equals money is… well, money. It cannot be overlooked that isolators allow for tighter, more agile, and less footprint-consuming aseptic manufacturing while also being more economical than competing solutions, cleanrooms in particular. Here, considerations must be given not only to initial infrastructure investments, but also ongoing, ancillary needs like maintenance, validation and personal protection equipment.

Considering all the factors in their favor, it’s little wonder why the isolator market in the United States is predicted to see significant growth through the end of this decade. From a valuation of just under $159 million in 2024, the isolator market is expected to experience a 6% CAGR through 2030. That would bring the market to just under $225 million – a 41.5% increase in just six years. 

Isolated, Together: The Value of Partnered Providers

Of course, projected growth is just that: projected. The anticipated uptick in isolator systems must be realized through tried-and-true solutions assessment, procurement and incorporation processes. Hovering over all of this is one lofty word: high. Highly potent drugs. High containment levels. Highly expensive (and sometimes scarce) APIs. And more than anything, the unacceptably high cost of failure. 

To meet this moment, pharma manufacturers must elevate their standards against a backdrop where a likely capacity crunch may limit options. This is a fundamental contradiction and must be corrected for pharma to move forward as ambitiously as medical science dictates. 

In a scenario where the largest isolator systems providers may experience lengthy delivery times, “off the shelf” solutions and a dearth of personalized service, a clear runway exists for medium-sized, discipline-specific providers to forge strategic partnerships yielding the levels of customization and differentiation that isolator systems can and should embody. For example, our two companies – one a provider of aseptic and containment isolation technology, the other a specialist in product filling and finishing solutions – are finding that the sum of our combined strengths is greater than the individual parts. By engaging us as a team, pharma manufacturers not only receive the benefit of two entities with deep knowledge in their respective segments, but also the ease of dealing with a single touchpoint for two key elements of aseptic manufacturing: reliable containment and precision fill-finish applications.

Such synergies also create efficiencies. At the front end of the process, having two or more partnered entities in frequent communication with each other lends itself to properly aligned aseptic manufacturing – one free of weak links or pain points. Factory acceptance tests (FATs) also become easier, since these joint solutions can be tested as one overarching line element. 

Finally, pharma manufacturers engaging medium-sized partnered entities enjoy the benefits of being big fish in a comparably small pond – a situation conducive to customized approaches and more expedient response times for post-installation maintenance, interventions or retrofits.

As aseptic pharma manufacturing continues to skew toward strictly contained and controlled production practices, the superiority of isolator systems is becoming clearer to a broader range of brand owners and contract manufacturers. As the pace of pharmacological innovation increases, so will demand for infrastructure partners capable of providing solutions that truly meet the mission-critical moment. 

Amit Ravona is Head of Business Development for RAVONA, which specializes in sophisticated aseptic and containment isolation technologies for the pharmaceutical and bioengineering sectors. 

Deborah Smook is VP of Marketing & Business Development for TurboFil Packaging Machines LLC, a supplier of liquid filling and assembly machines for the pharmaceutical and medical device industries.